Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

MediGene AG has successfully completed patient recruitment into its randomized Phase II trial of EndoTAG(TM)–1 for the treatment of triple receptor–negative breast cancer. Results will be available as scheduled in the first six months of 2010. This multinational clinical trial is being conduced across more than 20 centres in Europe and India.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address